AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01315431
Drug: Tesetaxel plus capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol.
Trial: NCT04464850
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin \<500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin \>800 mg/dl: discontinue iron sucrose
Trial: NCT04464850
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin \<500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin \>800 mg/dl: discontinue iron fumarate
Trial: NCT00742209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-control
Trial: NCT00835393
Drug: PROTONIX® 40 mg delayed-release tablets.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 40 mg
Trial: NCT02562066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
Trial: NCT03843060
Drug: AZD9977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.
Trial: NCT00638508
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
Trial: NCT00638508
Drug: Ketorolac and Ropivacaine
RxNorm normalized name: phenylephrine and ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
Trial: NCT03327844
Drug: RET using non-setting Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
Trial: NCT04347720
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous formulation
Trial: NCT04347720
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous and oral formulations
Trial: NCT04347720
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral formulations
Trial: NCT00918424
Drug: Oxcarbazepine Extended Release
RxNorm normalized name: oxcarbazepine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.
Trial: NCT02440464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
Trial: NCT03158103
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK162 at 30mg twice daily
Trial: NCT02001987
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
Trial: NCT02001987
Drug: csDMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
Trial: NCT02862236
Drug: Hypericum perforatum extract
RxNorm normalized name: Hypericum perforatum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.
Trial: NCT00489866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same as active drug.
Trial: NCT02845648
Drug: anticholinergic
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial anticholinergic therapy to all patients
Trial: NCT02635984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
Trial: NCT02770378
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
Trial: NCT02770378
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
Trial: NCT02770378
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
Trial: NCT01306266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
Trial: NCT01110590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04311294
Drug: Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
Trial: NCT00422604
Drug: GSK233705
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04074187
Drug: Corticosteroid treatment (Methylprednisolone or prednisolone)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
Trial: NCT04074187
Drug: Immunosuppressive treatment (eg, rituximab)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
Trial: NCT00697632
Drug: MGCD265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily administration without interruption
Trial: NCT00651274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
Trial: NCT04376931
Drug: Intravenous Solution
RxNorm normalized name: Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg.
Trial: NCT02912182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous NaCl intravenous administration Placebo tablets
Trial: NCT02912182
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT02690038
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline Ig \< 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization
Trial: NCT01406587
Drug: PP4001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, 1 dose every 12 hours x 4 doses
Trial: NCT01406587
Drug: PP4001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg, 1 dose every 12 hours x 4 doses
Trial: NCT01406587
Drug: PP4001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg, 1 dose every 12 hours x 4 doses
Trial: NCT01406587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 dose every 12 hours x 4 doses
Trial: NCT00395161
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)
Trial: NCT00003627
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03774355
Drug: CG1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
Trial: NCT03774355
Drug: CGL1802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
Trial: NCT01595347
Drug: Hyper-oxigenated fatty acid
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
Trial: NCT03867097
Drug: Placebo IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Trial: NCT02562573
Drug: PBI4050
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03289819
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
Trial: NCT00550459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet given once daily for 21 days
Trial: NCT00033397
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01742897
Drug: TTS-fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00254592
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
Trial: NCT00254592
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV once a day every 14 days x 2-4 cycles
Trial: NCT02962986
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
Trial: NCT01508884
Drug: Aqueous cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pretreatment with topical aqueous cream to the injection site before vaccination
Trial: NCT00266279
Drug: Oxaliplatin, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent, DOSE AND SCHEDULE (28-days cycle):~Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21
Trial: NCT02964247
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
Trial: NCT04720105
Drug: Duobrii®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
Trial: NCT02205073
Drug: Placebo RD + AVP SD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching to study drug) repeat doses + intranasal AVP single dose
Trial: NCT02205073
Drug: Placebo RD + Placebo SD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
Trial: NCT01869933
Drug: OC-10X
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01156545
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 40mg, once a day, oral intake, every day
Trial: NCT01156545
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40mg, once a day, oral intake, every day.
Trial: NCT01796678
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01796678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline or Sugar pill was given as placebo
Trial: NCT02696291
Drug: UV-4B Y mg (dose to be determined) oral solution
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Trial: NCT01987440
Drug: lubricating gel
RxNorm normalized name: Via Moisturizer For Her Lubricating Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00479986
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02508623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet BID for 60 days
Trial: NCT01161069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in oral solution, given once daily for 14 days
Trial: NCT04537884
Drug: UBX1325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug intravitreal injection
Trial: NCT05702333
Drug: Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.
Trial: NCT02092376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04430959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan placebo-matching tablets, orally, once daily for 4 weeks
Trial: NCT03758664
Drug: ICP-192
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,
Trial: NCT02147041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02338648
Drug: SUN-131 1.5% TDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transdermal patch
Trial: NCT02338648
Drug: Placebo TDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch for blinding
Trial: NCT04045769
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 tablets of placebo to be administered orally
Trial: NCT00000525
Drug: chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00314704
Drug: dopamine versus norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04413786
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo (24IU)
Trial: NCT00764881
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose
Trial: NCT00764881
Drug: Microgynon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
Trial: NCT00764881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
Trial: NCT01214655
Drug: LY2523355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Trial: NCT04234308
Drug: Catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
Trial: NCT01696123
Drug: MLC601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It was described
Trial: NCT04688645
Drug: Balanced crystalloid solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
Trial: NCT04688645
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
Trial: NCT02762929
Drug: HTX-011A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011A (bupivacaine/meloxicam), via injection.
Trial: NCT02762929
Drug: HTX-011B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011B (bupivacaine/meloxicam), via injection or instillation.
Trial: NCT02762929
Drug: HTX-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-002, via injection.
Trial: NCT02762929
Drug: HTX-009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-009, via injection.
Trial: NCT01308203
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
Trial: NCT01479075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02871011
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delivered as a footbath
Trial: NCT00102219
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01511042
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A hormone that is normally present in your body, which regulates your blood pressure.
Trial: NCT00002881
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no